Aptar Pharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aptar Pharma

Pharmaceutical Technology Europe

Company name: Aptar Pharma
Address: 36-38 rue de la Princesse, 78430 Louveciennes, France
Telephone: +33 1 39 17 20 20
Fax: +33 1 39 58 12 98
E-mail: guillaume.le_brun@aptar.com
Website: www.aptar.com
No. of employees: 2 280
Date founded: 1947

Aptar Pharma is the segment within the Aptargroup family dedicated to the pharmaceutical market. We create innovative drug delivery systems that meet the evolving needs of biotechnology, healthcare and pharmaceutical companies around the world.

Aptar Pharma is market driven with a strong focus on specific therapeutic areas such as as allergic rhinitis, asthma, COPD, pain management, hormone therapies, mucosal vaccines as well as cough & cold ailments.

The Aptar Pharma Prescription Division specializes in novel drug delivery solutions - i.e. pMDIs, DPIs, Spray Pumps and UnitDoses - specific to physician-prescribed medicines while the Consumer Health Care Division offers dispensing solutions adapted to over-the-counter medications.

Our manufacturing facilities are located in Buenos Aires (Argentina), Congers (NY, U.S.A.), Eigeltingen (Germany), Lugano (Switzerland), Le Vaudreuil and Val-de-Reuil (France) and Suzhou (near Shanghai, R.O.C.).

Approximately 6% of Aptar Pharma’s annual turnover is dedicated to research, development and industrialization of novel products. Our R&D and Marketing staff work closely together in a global market-focused team of 200 people dedicated to satisfying customer needs.

Aptar Pharma R&D centres of excellence are located in Eigeltingen (Germany), Lugano (Switzerland), Le Vaudreuil and Val-de-Reuil (France).

www.aptar.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology Europe,
Click here